Benzinga | Nov 8, 2021 07:21AM EST

Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $34

Oppenheimer analyst Leland Gershell maintains Protara Therapeutics (NASDAQ:TARA) with a Outperform and raises the price target from $32 to $34.